Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product cabozantinib while advancing a promising pipeline led by zanzalintinib. According to ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Future Oncol. 2013;9(10):1533-1548. The dual targeting of VEGF and EGFR was considered a logical treatment approach. Many data from Phase II studies have suggested that erlotinib may facilitate ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...

Cabozantinib is approved under the brand ... The drug is approved for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, and for adult and ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...